European Regulatory Watch

September 15th 2023

The safety profile of erdafitinib observed in THOR was consistent with the previously reported safety profile of erdafitinib in metastatic urothelial carcinoma (mUC).

August 31st 2023

The updated vaccine will be ready to ship following a positive European Commission review.

August 24th 2023

The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.

August 17th 2023

The indication for Pombiliti is a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).